Target |
Application |
Progress |
Collaborator/Sponsor |
P. Vivax |
Novel anti-malarials |
Drug Repositioning; |
Johns Hopkins Bloomberg School of Public Health; Bill & Melinda Gates Foundation GCE award |
Trypanosoma brucei |
Human African Trypanosomiasis |
Experimentally Validated Compounds |
University of Georgia; NIH SBIR phase I grant 1R43AI114078-01 |
Mycobacterium tuberculosis |
Tuberculosis |
Experimentally Validated Compounds | |
Nrf2 |
Neurodegeneration |
Design of NCEs |
NeuRho Farmaceutica Inc.; Michael J Fox Foundation for Parkinson's Research |
FAAH; MAGL |
Schizophrenia |
Experimentally Validated Compounds |
University of Texas Health Science Center - San Antonio; NIH SBIR phase I grant 1R43MH101892-01 |
Tau |
Neurodegeneration |
Experimentally Validated Compounds | |
Renin |
Hypertension diagnostics |
Experimental Validation |
EU Fund for Regional Development |
projects
Current Projects